Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been shown to have po-tent antitumor effects against human non–small-cell lung can-cer (NSCLC) cell growth; however, the mechanism of such an effect is not elucidated. Here, we demonstrate that erlotinib-induced cell growth inhibition in EGFR high-expressing human H322 NSCLC cells was accompanied by G1/S phase arrest, which was largely caused by a decrease in expression of G1/ S-related cyclins, suppression of activities of cyclin-dependent kinase (CDK) 2 and CDK4, induction of CDK inhibitor p27KIP1, and retinoblastoma hypophosphorylation. To further under-stand the role of p27KIP1 in G1/S arrest and cell growth inhibi-tion by erlotinib, we de...
Malignant pleural mesothelioma (MPM) is an aggressive chemotherapy-resistant cancer. Up-regulation o...
We have previously reported that the green tea polyphenol epigallocatechin-3-gallate (EGCG) and the ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...
<div><p>Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor recepto...
Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor receptor (EGFR)...
IntroductionDespite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyro...
Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant g...
Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant g...
Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor receptor (EGFR)...
<p>(a) Exposure to erlotinib in MTS assay: HCC827 (EGFR exon 19 deletion) exhibited significant grow...
<p>The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant cell line H1975 wer...
PurposeAcquired resistance to erlotinib in patients with EGFR-mutant non-small cell lung cancer can ...
Constitutive activation of EGFR due to overexpression or muta-tion in tumor cells leads to dysregula...
The emergence of resistance to EGF receptor (EGFR) inhibitor therapy is a major clinical problem for...
Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) plays an imp...
Malignant pleural mesothelioma (MPM) is an aggressive chemotherapy-resistant cancer. Up-regulation o...
We have previously reported that the green tea polyphenol epigallocatechin-3-gallate (EGCG) and the ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...
<div><p>Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor recepto...
Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor receptor (EGFR)...
IntroductionDespite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyro...
Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant g...
Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant g...
Gefitinib and erlotinib are anticancer agents, which inhibit epidermal growth factor receptor (EGFR)...
<p>(a) Exposure to erlotinib in MTS assay: HCC827 (EGFR exon 19 deletion) exhibited significant grow...
<p>The erlotinib sensitive cell lines HCC827 and PC9 and the erlotinib-resistant cell line H1975 wer...
PurposeAcquired resistance to erlotinib in patients with EGFR-mutant non-small cell lung cancer can ...
Constitutive activation of EGFR due to overexpression or muta-tion in tumor cells leads to dysregula...
The emergence of resistance to EGF receptor (EGFR) inhibitor therapy is a major clinical problem for...
Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) plays an imp...
Malignant pleural mesothelioma (MPM) is an aggressive chemotherapy-resistant cancer. Up-regulation o...
We have previously reported that the green tea polyphenol epigallocatechin-3-gallate (EGCG) and the ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...